Welcome to our dedicated page for Nektar Therapeutics SEC filings (Ticker: NKTR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nektar Therapeutics filings document the regulatory record of a Delaware clinical-stage biotechnology issuer with common stock listed on the Nasdaq Capital Market under NKTR. The company's 8-K reports cover financial results, Regulation FD clinical disclosures for rezpegaldesleukin, material definitive agreements, underwriting arrangements, at-the-market equity distribution mechanics, and shelf-registration-related offerings.
Proxy materials describe annual meeting matters, director elections, equity incentive plan authorization, auditor ratification, executive compensation votes, and governance procedures. Nektar's filing record also reflects capital-structure disclosures for common stock and pre-funded warrants, clinical-stage pipeline risks, research and development funding needs, and public-company controls tied to its immunology drug development business.
Nektar Therapeutics entered into an Equity Distribution Agreement with Guggenheim Securities and H.C. Wainwright, allowing at-the-market offerings of up to $150,000,000 of common stock under its automatic shelf registration. The agents will receive a 3.0% commission on gross sales and customary indemnification and expense reimbursement.
The company also announced that interim Chief Financial Officer Sandra Gardiner will retire and step down effective May 15, 2026. FLG Partners’ Linda Rubinstein will become interim Chief Financial Officer and principal financial and accounting officer under an amended consulting agreement with FLG at $650 per hour, terminable on 15 days’ notice.
Nektar Therapeutics reported a first-quarter 2026 net loss of $44.9 million on total revenue of $10.9 million, all from non-cash royalty revenue tied to previously sold royalty streams. Operating expenses were $49.9 million, driven mainly by research and development spending.
The company’s cash and investments in marketable securities rose sharply to $731.6 million as of March 31, 2026, supported by recent equity offerings and at-the-market sales that generated net proceeds of $1.07 billion between July 2025 and April 2026. Shares of common stock outstanding were 33,786,032 on May 1, 2026.
Nektar Therapeutics reported first quarter 2026 results showing a smaller loss and a much stronger balance sheet. Revenue was $10.9 million, slightly above $10.5 million a year ago, primarily from non-cash royalty revenue.
Net loss narrowed to $44.9 million, or $1.82 per share, compared with a $50.9 million loss, or $3.62 per share, in the first quarter of 2025. Research and development spending rose to $35.7 million as the company prepared a Phase 3 program for rezpegaldesleukin in atopic dermatitis, while general and administrative costs fell to $13.4 million mainly from lower legal expenses.
Cash and investments in marketable securities totaled $731.6 million at March 31, 2026, up from $245.8 million at December 31, 2025, and exclude approximately $351 million of net proceeds from a secondary offering completed on April 23, 2026. Management highlighted plans to initiate the Phase 3 ZENITH-AD program by July and to hold an End-of-Phase 2 meeting for alopecia areata this quarter.
FMR LLC reports beneficial ownership of 4,303,188.37 shares of Nektar Therapeutics common stock, representing 15.0% of the class as of 03/31/2026. The filing lists related interests held by Fidelity Growth Company Fund (5.6%, 1,608,001 shares) and Fidelity Growth Company Commingled Pool (6.5%, 1,861,842 shares) as of 03/31/2026. The schedule is filed under an amendment and is signed by an authorized representative pursuant to a Power of Attorney.
Nektar Therapeutics is asking stockholders to vote at its 2026 virtual annual meeting on June 4, 2026. Proposals include electing CEO Howard W. Robin to the board, amending the 2017 Performance Incentive Plan to add 3,000,000 shares, ratifying Ernst & Young LLP as auditor for 2026, and approving an advisory say-on-pay vote on executive compensation.
The proxy also details board structure, committee responsibilities, related-party review, and ownership data, including 29,679,647 common shares outstanding as of April 6, 2026, and major holders such as FMR LLC with 10.2% of the stock.
Nektar Therapeutics is raising new equity capital through an upsized underwritten public offering of 3,532,609 shares of common stock at $92.00 per share, with underwriters exercising a 30-day option for an additional 529,891 shares in full.
The company expects gross proceeds of about $325 million and estimates net proceeds of approximately $350.9 million after underwriting discounts and expenses. All shares are being sold by Nektar, and the deal is expected to close on April 23, 2026, subject to customary conditions.
Nektar plans to use the net proceeds for general corporate purposes, including research and development, clinical development such as Phase 3 trials for its lead candidate rezpegaldesleukin in atopic dermatitis and alopecia areata, and manufacturing costs to advance its drug pipeline.
Nektar Therapeutics is offering 3,532,609 shares of its common stock pursuant to a prospectus supplement, at a public offering price of $92.00 per share. The offering is expected to yield approximately $305.1 million in net proceeds before expenses (about $350.9 million if the underwriters exercise their full 30-day option for 529,891 additional shares). Shares outstanding used for this offering are stated as 29,679,647 shares as of April 1, 2026. The company intends to use proceeds for general corporate purposes, including research and development, clinical development (including Phase 3 trials for rezpegaldesleukin in atopic dermatitis and alopecia areata), and manufacturing costs to advance its drug candidates.
Nektar Therapeutics is offering $250,000,000 of common stock and, in lieu of shares for certain investors, pre-funded warrants exercisable for common stock, pursuant to a preliminary prospectus supplement dated April 20, 2026. The offering is part of a shelf registration and is subject to completion; proceeds are intended for general corporate purposes including research, clinical development and manufacturing for rezpegaldesleukin and other programs.
The company reported preliminary cash and marketable securities of approximately $741.7 million as of April 1, 2026 and completed an at-the-market program that raised about $110.0 million from 1,532,850 shares sold at a weighted average price of $71.76. Outstanding common shares used for offering calculations are 29,679,647 as of April 1, 2026.
Nektar Therapeutics is offering $250,000,000 of common stock and, in lieu of shares for certain investors, pre-funded warrants exercisable for common stock, pursuant to a preliminary prospectus supplement dated April 20, 2026. The offering is part of a shelf registration and is subject to completion; proceeds are intended for general corporate purposes including research, clinical development and manufacturing for rezpegaldesleukin and other programs.
The company reported preliminary cash and marketable securities of approximately $741.7 million as of April 1, 2026 and completed an at-the-market program that raised about $110.0 million from 1,532,850 shares sold at a weighted average price of $71.76. Outstanding common shares used for offering calculations are 29,679,647 as of April 1, 2026.
Nektar Therapeutics furnished an update on its liquidity position. The company reported having approximately $741.7 million in cash and investments in marketable securities as of April 1, 2026. This figure is an estimate based on information available at that time and is not a full statement of operating results or overall financial position.
Nektar Therapeutics furnished an update on its liquidity position. The company reported having approximately $741.7 million in cash and investments in marketable securities as of April 1, 2026. This figure is an estimate based on information available at that time and is not a full statement of operating results or overall financial position.